# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from...
Citigroup analyst David Lebowitz maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $178 to...
Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price targ...
Oppenheimer analyst Leland Gershell reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target f...
Goldman Sachs analyst Paul Choi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $180 to ...
BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by l...
Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia.